Anticholinergic effects of drugs and cognition in the elderly

Primary Psychiatry

Volumn 16, Issue 5, 2009, Pages 19-21

  Robinson, Donald S ^a  

^a Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; FLURAZEPAM; HALOPERIDOL; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENOBARBITAL; PHYSOSTIGMINE; PROMAZINE; PROMETHAZINE; PSYCHOTROPIC AGENT; SCOPOLAMINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGED; ALZHEIMER DISEASE; AMNESIA; ANTICHOLINERGIC EFFECT; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DROWSINESS; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; MEMORY DISORDER; RECALL; REVIEW;

EID: 75449091586     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163 (22):2716-2724. Erratum in: Arch Intern Med. 2004;164(3):298.
2. Fick DM, Waller JL Maclean JR, et al. Potentially inappropriate medication use in a Medicare managed care population: association with higher costs and utilization. J Managed Care Pharm. 2001;7:407-413.
3. Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol. 2008;28(6):644-659.
4. Mort JR, Aparasu. Prescribing potentially inappropriate medications to the ambulatory elderly. Arch Intern Med. 2001;160(18):2825-2831.
5. Cancelli I, Valentinis L, Merlino G, Valente M, Gigli GL. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther. 2008;84(1):63-68.
6. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Harman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:141-160.
7. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992;149(10):1393-1394.
8. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198-203.
9. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Réglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: result from the PAQUID Study. Br J Clin Pharmacol. 2005;59(2):143-151.
10. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: a longitudinal cohort study. BMJ. 2006;332(7539):455-459.
11. Thienhaus OJ, Allen A, Bennett JA, Chopra YM, Zemlan FP. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci. 1990;240(1):28-33.